دورية أكاديمية
أعرض في EDS

Molecular nociceptive mechanisms in migraine: The migraine cascade.

التفاصيل البيبلوغرافية
العنوان: Molecular nociceptive mechanisms in migraine: The migraine cascade.
المؤلفون: Guo S; Danish Headache Center, Department of Neurology, Translational Research Center, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.; Department of Neurology, Zealand University Hospital, Roskilde, Denmark., Christensen SL; Danish Headache Center, Department of Neurology, Translational Research Center, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark., Al-Karagholi MA; Danish Headache Center, Department of Neurology, Translational Research Center, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark., Olesen J; Danish Headache Center, Department of Neurology, Translational Research Center, Rigshospitalet-Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.
المصدر: European journal of neurology [Eur J Neurol] 2024 Aug; Vol. 31 (8), pp. e16333. Date of Electronic Publication: 2024 Jun 18.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2014- > : Oxford : Wiley
Original Publication: Oxford ; New York : Rapid Communications, [1994-
مواضيع طبية MeSH: Migraine Disorders*/drug therapy , Migraine Disorders*/metabolism , Migraine Disorders*/physiopathology , Pituitary Adenylate Cyclase-Activating Polypeptide*/metabolism , Nociception*/physiology , Nociception*/drug effects, Humans ; Animals ; Calcitonin Gene-Related Peptide/metabolism
مستخلص: Objective: This review will explore the categorization of migraine-provoking molecules, their cellular actions, site of action and potential drug targets based on the migraine cascade model.
Methods: Personal experience and literature.
Results: Migraine impacts over 1 billion people worldwide but is underfunded in research. Recent progress, particularly through the human and animal provocation model, has deepened our understanding of its mechanisms. This model have identified endogenous neuropeptides such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP) that induces controlled migraine-like attacks leading to significant discoveries of their role in migraine. This knowledge led to the development of CGRP-inhibiting drugs; a groundbreaking migraine treatment now accessible globally. Also a PACAP-inhibiting drug was effective in a recent phase II trial. Notably, rodent studies have shed light on pain pathways and the mechanisms of various migraine-inducing substances identifying novel drug targets. This is primarily done by using selective inhibitors that target specific signaling pathways of the known migraine triggers leading to the hypothesized cellular cascade model of migraine.
Conclusion: The model of migraine presents numerous opportunities for innovative drug development. The future of new migraine treatments is limited only by the investment from pharmaceutical companies.
(© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
References: Circ Res. 2007 Jun 8;100(11):1569-78. (PMID: 17556670)
Sci Transl Med. 2015 Oct 7;7(308):308ra157. (PMID: 26446954)
Brain. 2014 Nov;137(Pt 11):2951-9. (PMID: 25161294)
Drug Discov Today. 2017 Jul;22(7):1103-1111. (PMID: 28476535)
Mol Cell Pharmacol. 2009;1(5):264-270. (PMID: 20336186)
Headache. 2018 May;58(5):700-714. (PMID: 29446063)
Cephalalgia. 2019 Dec;39(14):1827-1837. (PMID: 31288556)
Nat Rev Neurol. 2018 Jun;14(6):338-350. (PMID: 29691490)
Cephalalgia. 2018 Mar;38(3):452-465. (PMID: 28952321)
Lancet. 1997 Feb 8;349(9049):401-2. (PMID: 9033475)
Brain. 2003 Jan;126(Pt 1):241-7. (PMID: 12477710)
Cephalalgia. 2021 Dec;41(14):1413-1426. (PMID: 34407650)
J Neurosci. 2009 Jul 8;29(27):8798-804. (PMID: 19587287)
J Headache Pain. 2020 Dec 2;21(1):137. (PMID: 33267788)
Cephalalgia. 2010 Feb;30(2):170-8. (PMID: 19489890)
Cephalalgia. 2010 Jan;30(1):27-36. (PMID: 19438925)
Brain Res Brain Res Rev. 2005 Jul;49(1):65-76. (PMID: 15960987)
Peptides. 2015 Dec;74:33-42. (PMID: 26417835)
Pain. 2021 Oct 1;162(10):2512-2520. (PMID: 34252916)
J Neurosci. 2021 May 26;41(21):4697-4715. (PMID: 33846231)
Cephalalgia. 2022 Feb;42(2):93-107. (PMID: 34816764)
J Headache Pain. 2022 Dec 5;23(1):155. (PMID: 36471250)
Eur J Neurol. 1994 Sep;1(1):73-80. (PMID: 24283432)
Cephalalgia. 2022 Nov;42(13):1425-1435. (PMID: 35796522)
Cephalalgia. 2017 Feb;37(2):114-124. (PMID: 26994300)
Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):94-9. (PMID: 1698266)
Cephalalgia. 2020 Oct;40(11):1212-1223. (PMID: 32594760)
Cephalalgia. 1995 Apr;15(2):94-100. (PMID: 7641257)
Ann Neurol. 2021 Jun;89(6):1157-1171. (PMID: 33772845)
Brain. 2009 Jan;132(Pt 1):16-25. (PMID: 19052139)
Eur J Neurosci. 2006 Nov;24(10):2691-3. (PMID: 17156195)
Cephalalgia. 2021 Jan;41(1):33-44. (PMID: 33231489)
Eur J Neurol. 2024 Aug;31(8):e16333. (PMID: 38894592)
Clin Exp Pharmacol Physiol. 2002 Apr;29(4):312-6. (PMID: 11985542)
Eur J Pharmacol. 2014 Oct 5;740:97-102. (PMID: 24998872)
Cephalalgia. 2014 Oct;34(11):877-86. (PMID: 24563332)
Physiol Rev. 1997 Oct;77(4):1165-232. (PMID: 9354814)
Cephalalgia. 2020 Jan;40(1):57-67. (PMID: 31299857)
Pain. 2018 Nov;159(11):2306-2317. (PMID: 29994995)
Cephalalgia. 2002 Feb;22(1):54-61. (PMID: 11993614)
Brain. 2023 Dec 1;146(12):5224-5234. (PMID: 37540009)
Neuroreport. 1993 Aug;4(8):1027-30. (PMID: 8241457)
N Engl J Med. 2020 Nov 5;383(19):1866-1876. (PMID: 33211930)
Front Neuroanat. 2022 Oct 26;16:991403. (PMID: 36387999)
JAMA. 2021 Jun 15;325(23):2348-2356. (PMID: 34128999)
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4274-9. (PMID: 15016917)
Neurobiol Dis. 2012 Jan;45(1):633-44. (PMID: 22033344)
Pain. 2014 Feb;155(2):269-274. (PMID: 24121068)
Brain. 2019 Sep 1;142(9):2644-2654. (PMID: 31292608)
Brain. 2019 Jan 1;142(1):93-102. (PMID: 30590467)
Neuroreport. 1995 Jul 31;6(11):1475-9. (PMID: 7579128)
Cephalalgia. 2012 Mar;32(4):337-45. (PMID: 22421901)
Brain. 2022 Jul 29;145(7):2450-2460. (PMID: 35136961)
Pharmaceuticals (Basel). 2010 Jun 17;3(6):1966-1987. (PMID: 27713337)
Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):213-25. (PMID: 8878050)
Trends Pharmacol Sci. 1994 May;15(5):149-53. (PMID: 7538702)
J Mol Cell Cardiol. 2005 Jul;39(1):99-112. (PMID: 15953614)
Int J Mol Sci. 2020 Jan 21;21(3):. (PMID: 31973098)
J Neural Transm (Vienna). 2020 Apr;127(4):431-444. (PMID: 32088764)
J Cereb Blood Flow Metab. 2017 Apr;37(4):1182-1191. (PMID: 28155572)
Cephalalgia. 2018 Jul;38(8):1471-1484. (PMID: 29022756)
Eur J Pharmacol. 2005 Oct 3;521(1-3):105-14. (PMID: 16182282)
Cephalalgia. 2020 Jun;40(7):650-664. (PMID: 32418458)
Neurology. 2021 May 18;96(20):e2488-e2499. (PMID: 33827963)
Lancet Neurol. 2009 Jul;8(7):679-90. (PMID: 19539239)
Cephalalgia. 2021 Mar;41(3):329-339. (PMID: 33059476)
Cephalalgia. 2020 Aug;40(9):924-934. (PMID: 32223300)
Headache. 2008 Sep;48(8):1202-13. (PMID: 18647185)
Eur J Neurol. 2012 May;19(5):703-11. (PMID: 22136117)
Nat Rev Neurol. 2017 Dec;13(12):713-724. (PMID: 28984313)
فهرسة مساهمة: Keywords: CGRP; PACAP; animal model; experimental headache; human provocation model; migraine; migraine trigger
المشرفين على المادة: 0 (Pituitary Adenylate Cyclase-Activating Polypeptide)
JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
تواريخ الأحداث: Date Created: 20240619 Date Completed: 20240706 Latest Revision: 20240727
رمز التحديث: 20240727
مُعرف محوري في PubMed: PMC11235602
DOI: 10.1111/ene.16333
PMID: 38894592
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-1331
DOI:10.1111/ene.16333